The impact of prolactin elevation with antipsychotic medications on subjective quality of life in patients with Schizophrenia

Clinical Neuropharmacology

Volumn 26, Issue 4, 2003, Pages 182-184

  Kaneda, Yasuhiro ^a  

^a Psychiatric Hospital at Vanderbilt   (United States)

Author keywords

Antipsychotic agents; Prolactin; Quality of life; Schizophrenia

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; PROLACTIN; TESTOSTERONE;

ADULT; ANXIETY DISORDER; ARTICLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; DEPRESSION; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HOSTILITY; HUMAN; HYPERPROLACTINEMIA; JAPAN; MALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; QUALITY OF LIFE; RATING SCALE; REGRESSION ANALYSIS; SCHIZOPHRENIA; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL; THOUGHT DISORDER;

ADULT; ANTIPSYCHOTIC AGENTS; CROSS-SECTIONAL STUDIES; HUMANS; MALE; MIDDLE AGED; PROLACTIN; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; REGRESSION ANALYSIS; SCHIZOPHRENIA;

EID: 0041633793     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-200307000-00006     Document Type: Article

References (14)

1. Karow A, Naber D. Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology (Berl). 2002;162:3-10.
2. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999;281:537-544.
3. Maguire GA. Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psychiatry. 2002;63(suppl 4):56-62.
4. Gutierrez MA, Stimmel GL. Management of and counseling for psychotropic drug-induced sexual dysfunction. Pharmacotherapy. 1999;19:823-831.
5. Winters SJ, Troen P. Altered pulsatile secretion of luteinizing hormone in hypogonadal men with hyperprolactinaemia. Clin Endocrinol (Oxf). 1984;21:257-263.
6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). Washington, DC: American Psychiatric Association; 1994.
7. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799-812.
8. Inada T. Evaluation and Diagnosis of Drug-Induced Extrapyramidal Symptoms: Commentary on the DIEPSS and guide to its usage [in Japanese]. Tokyo: Seiwa Shoten; 1996.
9. Guy W. ECDU Assessment Manual. Rockville: US Department of Health, Education, and Welfare; 1976.
10. Kaneda Y, Imakura A, Fujii A, et al. The Schizophrenia Quality of Life Scale: validation of the Japanese version. Psychiatry Res. 2002;113:107-113.
11. Wilkinson G, Hesdon B, Wild D, et al. Self-report quality of life measure for people with schizophrenia: the SQLS. Br J Psychiatry. 2000;177:42-46.
12. Tollefson GD, Andersen SW. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life? J Clin Psychiatry. 1999;60(suppl 5):23-29.
13. Voruganti LN, Heslegrave RJ, Awad AG. Quality of life measurement during antipsychotic drug therapy of schizophrenia. J Psychiatry Neurosci. 1997;22:267-274.
14. Gerlach J, Larsen EB. Subjective experience and mental side-effects of antipsychotic treatment. Acta Psychiatr Scand Suppl. 1999;395:113-117.